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vhe past year was an exciting one in cardiovascular medi-
ine, with both advances, as well as disappointments and
ontroversy. Important technical advances in imaging oc-
urred not only in computed tomography (CT) angiography
nd magnetic resonance imaging (MRI) but also in more
stablished fields such as echocardiography. In the field of
nterventional cardiology the issue of stent thrombosis with
rug-eluting stents took center stage, but should not eclipse
ther important developments in left main stenting as well
s noncoronary interventions. The treatment of angina was
dvanced with the introduction of a new antinginal drug,
anolazine, while the hope for a new high-density lipopro-
ein (HDL) raising drug, torcetrapib, were dashed.
Many of these developments were reported in the pages
f JACC. As in previous years, in the following paper the
ditors have summarized the key JACC articles in their
espective areas: imaging, coronary disease, interventional
ardiology, heart failure, electrophysiology, congenital and
ediatric heart disease, and basic science. Undoubtedly not
ll excellent studies could be included in this review, but an
ttempt was made to highlight those articles that, in the
pinion of the editors, were most noteworthy. As in past
ears this Highlights article will replace the Editor’s Page
or January.
chocardiography
ontrast echocardiography. Considerable research effort
ontinues to be directed toward the development of contrast
chocardiography. A major application of contrast would be
n enhancing quantitation by echocardiography. In a study
f 100 patients comparing unenhanced and contrast en-
anced echocardiography, MRI, and cineangiography,
offmann et al. (1) demonstrated that contrast-enhanced
chocardiography exhibited the highest interobserver agree-
ent and greatest accuracy in detecting regional wall
rom the *Cardiology Division, University of California–San Diego, San Diego,
alifornia; ‡Veterans Affairs Medical Center, San Diego, California; University of
alifornia Irvine, Irvine, California; †Duke University, Durham, North Carolina;
Johns Hopkins Hospital, Baltimore, Maryland; and ¶Pediatric Cardiology, Oregont
ealth and Science University, Portland, Oregon.
Manuscript received November 30, 2006; accepted December 5, 2006.otion abnormalities. These data added to the accumulat-
ng evidence that contrast administration cannot only rescue
echnically difficult echocardiograms for the evaluation of
eft ventricular (LV) structure and function but can yield
eproducibility and accuracy comparable to MRI. In an
ccompanying editorial, Bolger (2) commented that the
esults of these studies showed that considerable interob-
erver variability exists even for the best imaging techniques
nterpreted by the most experienced observers. Progress
ontinues with myocardial perfusion by contrast echocardi-
graphy. In the first large multicenter clinical study pub-
ished evaluating the ability of myocardial contrast echocar-
iography (MCE) to detect coronary stenoses, Jeetley et al.
3) reported the results of comparing MCE with single-
hoton emission computed tomography (SPECT) using
tandard coronary angiography as the independent standard.
o differences existed in the sensitivity or specificity of
CE versus SPECT (84% vs. 82% and 56% vs. 52%,
espectively). Thus, this multicenter study provides evidence
hat MCE is equivalent to SPECT in the detection of
oronary stenoses. A new application for contrast echocar-
iography consisting of visualizing of the vasa vasorum and
therosclerotic plaque in the coronary arteries was described
y Feinstein (4). Contrast administration not only dramat-
cally enhanced the delineation of the intimal surface of the
arotids, but also visualized the presence of luxuriant growth
f the vasa vasorum and of inter-plaque vasculature of
therosclerotic lesions. These data raise the exciting poten-
ial that contrast echocardiography might have an important
ole in identifying vulnerable carotid plaques and in study-
ng the blood flow to atheroma that might be analogous to
hat of tumors.
ssessment of aortic stenosis. Prior studies have demon-
trated that measurement of effective orifice area (EOA)
erived by Doppler techniques in the setting of aortic
tenosis manifests flow-dependent changes, raising ques-
ions regarding the accuracy of the method. Kadem et al. (5)
tudied whether these flow-dependent changes in aortic
alve EOA represent real findings or artifacts. With an in
itro model in which all variables could be closely con-
rolled, they observed flow-dependent changes in EOA
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Highlights From JACC in 2006 January 30, 2007:509–27elated to changes in flow volume. They concluded that
hese changes are not artifacts but represent real alterations
hat are explained by either the presence of unsteady effects
t low flow rates or by an increase in valve leaflet opening.
herefore, effective orifice determinations made by Doppler
n patients with aortic stenosis can be used for clinical
ecision making. In an accompanying editorial, Baumgart-
er (6) pointed out that in, certain subsets of patients with
ortic stenosis, more sophisticated approaches might be
ecessary to provide measurements precise enough to guide
ppropriate clinical management, particularly in patients
ith aortic valve areas in the range of 0.8 to 1.0 cm2.
issue Doppler echocardiography. Evidence continues to
ount that tissue Doppler echocardiography and the ex-
rapolated measurements of strain and torsion can be of
reat value in assessing regional myocardial performance. In
combined experimental and clinical study, Skulstad et al.
7) compared the ability of the tissue Doppler recording
odalities of velocity, strain, and displacement to quantita-
ively assess regional myocardial systolic function. They
easured these variables at baseline and during occlusion of
he left anterior descending coronary artery in 10 canines
ith sonomicrometry as a standard. They demonstrated that
ystolic strain correlated very well with segmental shorten-
ng and work and differentiated both moderately and se-
erely ischemic myocardium from normal. They also studied
0 patients with acute anterior infarction and 15 control
ubjects. In this clinical study they observed that systolic
train differentiated well between infarcted and normal
yocardium, whereas displacement and ejection velocity
howed overlap. They concluded that tissue Doppler echo-
ardiography provides an excellent modality to assess the
unction of segmental ischemic myocardium and that strain
easurements are clearly superior to other formulations in
his regard. Another study from the same institution by
mundsen et al. (8) sought to validate the accuracy of
yocardial strain measurements obtained by speckle track-
ng echocardiography. Strain measurements obtained by
peckle tracking in the long and short axis views were
ompared with data derived by sonomicrometry in canine
xperiments. They observed a good correlation between
train measurements by ultrasound and sonomicrometry in
oth the long and short axis (r 0.90 and 0.79, respectively,
 0.001 for both). They also compared strain measure-
ents by speckle tracking in a group of humans with values
erived from tagged MRI examinations. They observed that
0% of segments were suitable for analysis, and that a good
orrelation existed between ultrasound and MRI (r  0.87,
 0.001). These studies provide strong evidence of the
bility of this new speckle tracking approach to accurately
easure myocardial strain in patients. The tracking ap-
roach is of particular value in enabling measurements of
train to be acquired in the short axis as well as in the
ongitudinal (apical) views.
ssessment of left atrial (LA) volume. It is now wellppreciated that LA volume is a reflection of chronic vntracardic pressures and as such is a valuable marker of the
resence and severity of heart disease. It is often said that
A volume is for heart disease as hemoglobin A1C is for
iabetes. Further evidence of the importance of LA volume
as provided by Tsang et al. (9) who compared the value of
A size measured as diameter, area, or volume in predicting
ardiovascular risk manifested by the development of a first
pisode of atrial fibrillation (AF), heart failure, stroke,
ransient ischemic attack, myocardial infarction (MI), cor-
nary revascularization, or death in 317 patients. Although
A size measured by any parameter was predictive of
ombined outcomes, LA volume yielded the best results in
redicting cardiovascular events (area under receiver-
perator characteristic curve  0.71). In addition, they
bserved a graded association between LA enlargement and
ardiovascular risk only for indexed LA volumes measured
y bi-plane techniques, and that increased LA volume is
learly associated with the risk of subsequent cardiovascular
vents except for the population of patients who experience
F. In another study from the same institution, Osranek et
l. (10) examined whether LA size could be used to predict
he occurrence of AF during the postoperative period in
atients undergoing cardiac surgery. They examined 205
atients undergoing cardiac surgery, and they observed AF
ostoperatively in 84 patients at a median of 1.8 days after
he procedure. Only age and LA volume were independent
redictors of postoperative AF, and patients with a LA
olume 32 ml/m2 had an almost 5-fold increased risk of
his complication. In view of the fact that postoperative AF
requently results in increased morbidity and mortality and
rolongs a hospital stay resulting in greater cost, the ability
o predict patients at high risk of this complication by virtue
f the presence of increased LA volume could be of
ignificant clinical value. In an accompanying editorial,
anning et al. (11) point out that several pharmacologic
gents have been shown to be of prophylactic value in
reventing postoperative AF and that LA volume provides
potential guide to the application of these agents in
ndividual patients.
ntravascular ultrasound (IVUS). Although IVUS has not
ound the role in interventional cardiology that was initially
nticipated, it has made a major contribution to the under-
tanding of the atherosclerotic process as well as providing a
ool to observe the behavior of atheromas over time. A study
y Sano et al. (12) analyzed the integrated backscatter of the
VUS images of 160 nonstenotic coronary lesions in 140
atients. The IVUS characteristics of 10 plaques that
ltimately caused acute coronary syndrome (ACS) during
ollow-up were compared with those plaques that did not.
ignificant differences in plaque burden, eccentricity, re-
odeling index, and percent lipid area were observed in the
ulnerable as opposed to these stable plaques. These data
emonstrate that IVUS examination can distinguish char-
cteristics of plaques that are high risk for developing a
linical ACS. In another IVUS study Nasu et al. (13)
alidated the accuracy of an in vivo technique for tissue
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January 30, 2007:509–27 Highlights From JACC in 2006haracterization with radiofrequency data analysis called
irtual Histology (Volcano Therapeutics, Inc., Rancho
ordova, California). The authors compared the radiofre-
uency IVUS data with histopathologic examination of
pecimens obtained by a single debulking directional coro-
ary atherectomy cut in 15 patients with stable angina
ectoris and 15 with ACS. They observed a range of
redictive accuracy of IVUS virtual histology of 87% to 96%
or fibrous, necrotic, and calcified regions. These data
ubstantiate the fact that IVUS tissue characterization can
e employed in identifying plaque characteristics in vivo.
pplication of echocardiography to clinical issues. One
f the major attributes of echocardiography is its ability to
ddress pathophysiological issues in humans. One such issue
s the continuing controversy of the role of a patent foramen
vale in cerebrovascular ischemia. Meissner et al. (14) from
he Mayo Clinic performed transesophageal echocardiogra-
hy in 585 randomly sampled subjects ages 45 years or older
ho were followed for a median of 5.1 years. A patent
oramen ovale was identified in 24.3% of these patients but
as not observed to be an independent risk factor for future
erebrovascular events. Actuarial event-free survival was less
or patients with an atrial septal aneurysm than without
81% vs. 93%, p  0.048). In an accompanying editorial,
eier (15) commented that, although these data did not
ompletely resolve the issue, they pointed out that the
revalence of events with patent foramen ovales is suffi-
iently small so that very large numbers of patients will need
o be randomized and followed to answer the question of
he etiologic role and efficacy of interventional therapy for
hese lesions. Two studies published this year address the
mportant issue of the effect of obesity upon the cardiovas-
ular system. In a study using strain measurements derived
rom tissue Doppler echocardiography, Wong et al. (16)
emonstrated that abnormalities of right ventricular func-
ion were present in obese individuals similar to abnormal-
ties previously shown in LV function. Chinali et al. (17)
eported data from the Strong Heart Study that both
verweight and obese adolescents had increased LV diam-
ters and mass on echocardiography and that this increase in
ass exceeded the anticipated hemodynamic need and was
ssociated with an increased LA force. In an editorial, von
aehling et al. (18) noted that, despite this impressive
chocardiographic evidence of cardiovascular abnormalities
ssociated with obesity, epidemiologic data indicate that
ncreased body weight might actually be protective after the
nset of cardiovascular abnormalities. Clearly the last word
n obesity has not been written. In another report, Shivalkar
t al. (19) used echocardiography to delineate abnormalities
f cardiac function associated with obstructive sleep apnea
OSA). They studied 43 patients without known heart
isease before and after treatment with continuous positive
irway pressure (CPAP). They identified multiple cardiac
bnormalities, involving both left and right ventricles that
ere significantly associated with the apnea-hypopma in-
ex. Significant improvement was observed after 6 months (f CPAP therapy. Thus, these data establish that OSA can
roduce changes in cardiac structure and function that are
eversible with CPAP therapy.
rug-Eluting Stents (DES)
fficacy. The ENDEAVOR-III trial (20) compared
obalt-based alloy zotarolimus-eluting coronary stents
ZES) with a phosphorylcholine polymer versus sirolimus-
luting stents (SES) in 436 patients undergoing elective
ercutaneous coronary intervention (PCI) of de novo native
oronary lesions. The primary end point, angiographic
n-segment late lumen loss, was significantly higher in ZES
ompared with SES (0.34 mm vs. 0.13 mm, p  0.001).
n-segment binary angiographic restenosis (11.7% vs. 4.3%,
 0.04) and target lesion revascularization (TLR) (9.8%
s. 3.5%, p  0.04) were also higher in the ZES group.
owever, in-hospital major adverse cardiac events (MACE)
ere significantly lower among patients treated with ZES
0.6% vs. 3.5%, p  0.04). Long-term differences between
tent types have not been determined, and it will be
nteresting to see whether a dichotomy emerges between
afety and efficacy of these fundamentally different stent
ypes, polymers, and drugs.
The 2-year safety and efficacy of SES compared with
are-metal stents (BMS) was reported in the RESEARCH
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardi-
logy Hospital) Registry and in the SIRIUS (Sirolimus-
luting Stent in de Novo Native Coronary Lesions) trial
21,22). In both studies, the overall MACE and target
essel revascularization (TVR) was significantly better with
ES, without a significant increase in death, MI, or stent
hrombosis. In addition, events beyond the 9-month win-
ow after mandated routine angiographic follow-up and the
culostenotic reflex, which was shown in a TAXUS sub-
tudy to strongly influence the rate of TVR and overesti-
ate the effectiveness of DES (23), were relatively few.
In the SCANDSTENT (Stenting Coronary Arteries in
on-Stress/Benestent Disease Trial) (24), 322 patients
ith symptomatic complex coronary artery disease (CAD)
occluded [36%], bifurcations [34%], ostial [22%], or angu-
ated [8%]) were randomized to SES versus BMS with a
rimary end point of minimal lumen diameter (MLD) at 6
onths after stent implantation. The SES showed better
LD (2.48 mm vs. 1.65 mm, p 0.001), diameter stenosis
19.3% vs. 43.8%, p  0.001), and restenosis (2.0% vs.
1.9%, p  0.001). The rate of MACE was 4.3% with SES
ersus 29.3% with BMS (p  0.001), and stent thrombosis
as observed in 0.6% in the SES group versus 3.1% in the
MS group (p  0.15).
Whether a clinical superiority exists between SES versus
aclitaxel-eluting stents (PES) is still being debated. In a
arge multicenter registry (25) of 1,676 patients receiving
ither SES or PES, SES was associated with a reduced
ncidence of MACE (9.2% vs. 14.1%, p  0.007) and TVR
5.0% vs. 10.0%, p  0.0008) compared with PES. This
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Highlights From JACC in 2006 January 30, 2007:509–27esult was consistent across most subgroups tested after
ropensity analysis accounting for baseline differences in
isk profile. The rates of death and MI were similar between
roups. Wessely et al. (26) succinctly reviewed the mecha-
isms of action, therapeutic range, release kinetics, and
linical outcomes of SES versus PES.
As the debate over safety of DES increases, alternative
nd improved methods to prevent restenosis will be needed.
he ORAR II (Oral Rapamycin After Coronary Bare-
etal Stent Implantation to Prevent Restenosis) trial (27)
howed in 100 patients randomized to either oral rapamycin
lus diltiazem or no therapy with BMS that the 1-year TVR
8.3% vs. 38%, respectively, p  0.001) and MACE (20%
s. 44%, respectively, p  0.018) were lower in the oral
apamycin group. Rapamycin was well tolerated (26% minor
ide effects) and was maintained in 96% of patients.
The role of DES in saphenous vein grafts (SVG) has not
een extensively studied. Vermeersch et al. (28) randomized
5 patients with SVG lesions to SES versus BMS. In-stent
ate loss (0.38 mm vs. 0.79 mm, p  0.001), restenosis
13.6% vs. 32.6%), neointimal volume, and TVR (5.3% vs.
7%, p 0.012) were reduced in SES compared with BMS.
he study was not powered to evaluate death and MI.
afety. Several studies addressed the increasing concern of
he long-term safety and effectiveness of DES. The long-
waited BASKET-LATE (Basel Stent Kosten Effektivitats
rial) (29) evaluated the incidence of late clinical events
from 6 to 18 months) and late stent thrombosis in DES
both SES and PES) versus BMS after clopidogrel discon-
inuation in 746 nonselected patients with 1,133 stented
esions surviving 6 months without MACE. Overall rates of
ardiac death/MI from 0 to 18 months were not different
etween DES and BMS patients. However, after clopi-
ogrel discontinuation (between months 7 and 18),
eath/MI occurred in 4.9% in the DES versus 1.3% in the
MS group. The TVR remained lower after DES, resulting
n similar rates of all clinical events for this time period
DES 9.3%, BMS 7.9%). Documented late stent thrombo-
is and related death/target vessel MI were twice as frequent
fter DES versus BMS (2.6% vs. 1.3%). Thrombosis-related
vents occurred between 15 and 362 days after clopidogrel
iscontinuation presenting as MI or death in 88%. This
tudy suggests that the early benefit of DES might be slowly
roded by increasing death/MI in the long term, particularly
fter clopidogrel discontinuation. It is not clear at this point
hether continued clopidogrel prevents such events and
hether late thrombotic events will continue to accrue after
8 months. This study emphasizes the importance of
atient and lesion selection as well as adequacy of clopi-
ogrel compliance in choosing DES compared with BMS.
Nebeker et al. (30), with clinical and autopsy data from
he adverse-device-event database of the Food and Drug
dministration (FDA) and the RADAR (Research on
dverse Drug/Device events And Reports) project, reported
n 17 cases of systemic and intrastent hypersensitivity
eactions that were probably or certainly caused by DES. vour autopsies confirmed eosinophilic inflammation,
hrombosis, and lack of intimal healing within the stents. As
clinical correlate in living patients, Kotani et al. (31), with
ngioscopy, showed that most DES exhibited incomplete
eointimal coverage 3 to 6 months after implantation,
hereas all BMS showed complete coverage. Finally, in the
RACI III (Argentine Randomized Trial of Coronary
tents Versus Bypass Surgery) study (32), it was demon-
trated that in patients receiving both DES or BMS in
ifferent arteries, both subacute and late stent thrombosis
ccurred predominantly in DES stents and mostly upon
lopidogrel withdrawal. These studies confirm that DES
isplay delayed healing compared with BMS, which is likely
he major factor in late adverse events with DES.
ost effectiveness. A cost-effectiveness analysis of the
AXUS-IV trial (33) showed that PES were cost effective
elative to other accepted medical therapies, showing a
-year cost difference of $572/patient with incremental
ost-effectiveness ratios of $4,678/TVR avoided and
47,798/quality-adjusted life year gained. In a study com-
aring cost-effectiveness of SES versus PES in high-risk
ohorts (diabetic patients or in-stent restenosis) in Ger-
any, initial hospital costs were similar between SES and
ES, whereas follow-up costs were higher for PES, mainly
wing to need for repeat TVR (34). These findings were put
nto perspective by Vaitkus (35) noting that, relative to the
merican health care system, the cost savings benefit the
verall health care system and the insurance companies,
hereas hospitals bear both the upfront stent costs and the
ecreased revenue due to reduced repeat procedures.
estenosis. The RIBS-II (Restenosis Intrastent: Balloon
ngioplasty Versus Elective Sirolimus-Eluting Stenting)
tudy (36), a multicenter trial randomizing 150 patients
ith BMS in-stent restenosis (ISR) to SES versus balloon
ngioplasty, showed a reduced incidence of recurrent reste-
osis (11% vs. 39%; p  0.001), TVR (11% vs. 30%; p 
.003), and event-free survival (freedom from death, MI,
nd TVR) in the SES group. These results were corrobo-
ated in the TRUE (Tuscany Registry of Sirolimus for
nselected In-Stent Restenosis) Registry, derived from a
eal-world setting in which SES were implanted for BMS
SR showing an ischemia-driven TLR of only 4.9% (37). It
s now clear that DES are effective for BMS in-stent
estenosis, but the optimal treatment of DES ISR has not
een defined yet.
eft main (LM) interventions. A series of publications
resented new data on unprotected LM PCI with DES. In
single-center observational series of 110 patients from the
ombined RESEARCH and T-SEARCH registries com-
aring SES and PES for LM disease at a median follow-up
f 660 days, the cumulative incidence of MACE (25% vs.
9%, p  0.74), TVR (9% vs. 11%), and late loss were
imilar (38). In a follow-up study from the same group,
algimigli et al. (39) showed that patients with distal LM
isease had a higher cumulative incidence of MACE (30%
s. 11%, p 0.007), primarily driven by higher rate of TVR
(
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January 30, 2007:509–27 Highlights From JACC in 200613% vs. 3%, p  0.02) and correspondingly higher rates of
ate loss. In these studies, stent technique did not seem to
nfluence the results, and there were no cases of early or late
tent thromboses. Another small, single-center study of 50
atients, with serial angiography at 3 and 9 months’ follow-
p, also suggested worse outcomes for distal LM stenting
ompared with nondistal LM interventions (40). Late loss
as significantly greater within the left circumflex (LCX)
stium compared with the LM body (0.83  0.89 mm vs.
.49  0.72 mm, p  0.04) with restenosis being primarily
focal process. Late loss continued to increase between 3-
nd 9-month follow-up. These studies suggest that LM
tenting is associated with good outcomes in nondistal LM
ites and that distal LM interventions will remain a chal-
enging subset in the near future.
Until randomized clinical trials are performed comparing
M stenting versus coronary artery bypass graft surgery
CABG), observational studies might provide insights into
hat we can expect when such trials are completed. In a
etrospective analysis, Lee at al. (41) compared the 6-month
utcomes of 123 patients undergoing CABG with 50
atients undergoing PCI with DES for unprotected disease.
he 30-day MACE was higher for CABG versus PCI (17%
nd 2%, p  0.01). The estimated MACE and stroke-free
urvival at 6 months and 1 year was 83% and 75%,
espectively, in the CABG group versus 89% and 83% in the
CI group (p  0.20). In this short-term report with the
bvious methodological limitations of a retrospective, non-
andomized study, the results for PCI were at least as good
s those of CABG. Baim et al. (42) provided a historical
erspective in an accompanying editorial suggesting that
road use of unprotected LM stenting, particularly in distal
ifurcation stenoses, is not warranted at this point and
hould only be used in selected patients with high surgical
isk and acceptable anatomical lesions.
In an additional study evaluating prognostic importance
f nonsignificant LM stenosis (50% diameter stenosis) in
,385 patients, Gyenes et al. (43) showed similar 7-year
rude mortality hazard ratio (HR) of PCI patients with
50% LM disease versus those with no LM CAD after risk
djustment for differences in baseline clinical profile. This
uggests that patients with 50% LM diameter stenosis are
ot at increased long-term risk of cardiovascular events.
oncoronary interventions—carotid, renal, and periph-
ral arterial disease. The CREATE (Carotid Revascular-
zation with ev3 Arterial Technology Evolution trial) reg-
stry evaluated the safety and efficacy of a new distal embolic
rotection system in 419 patients with severe carotid steno-
is and high-risk features for carotid endarterectomy (44).
echnical success was achieved in 97.4% of patients. The
rimary end point was present in 6.2% of patients (death:
.9%; nonfatal stroke: 3.3%; nonfatal MI: 1%). The overall
atal and nonfatal stoke incidence was 4.5%. These results of
verall MACE were relatively similar to other published
egistries and trials (SAPPHIRE [Stenting and Angioplasty
ith Protection in Patients at High Risk for Endarterec- Lomy], ARCHER [Acculink for Revascularization of Ca-
otids in High-Risk Patients], SECURITY [Stent in Pa-
ients at High Risk for Carotid Endarterectomy]).
A modest-sized study suggested that serial IVUS imaging
rovides insights into carotid in-stent restenosis and vessel
emodeling. Clark et al. (45) performed postprocedural and
-month follow-up quantitative carotid angiography and
VUS after self-expanding stent deployment in 50 internal
arotid arteries (ICA). They demonstrated continued (49%)
tent expansion over 6 months but a corresponding (37%)
oss of luminal area due to neointimal proliferation. In
ddition, a correlation was noted between stent expansion
nd neointimal proliferation.
The long-term results after directional atherectomy of
emoral-popliteal lesions was reported by Zeller et al. (46) in
prospective registry of 84 patients (100 legs and 131
esions) with symptomatic peripheral arterial disease. The
ean lesion length was 43 to 131 mm and the technical
uccess rate was 86%. Primary patency, defined as freedom
rom 50% restenosis detected by duplex at 18 months
anged from 42% to 73%, and secondary patency ranged
rom 67% to 89%, with de novo lesions having the better
utcomes. Randomized trials are awaited to assess whether
therectomy provides improved clinical outcomes compared
ith standard techniques.
De Bruyne et al. (47) advanced the field of renal artery
hysiology by defining both hyperemic renal flow as well as
hat constitutes significant renal artery stenosis with renal
rtery pressure gradients and flow velocity measurements. In
8 normotensive patients, quantitative angiographic mea-
urements of the renal artery were obtained, and renal artery
ressure and flow velocity were continuously recorded after
arious hyperemic agents. They determined that the normal
enal flow reserve averages approximately 2 in humans with
ormal renal function and that a bolus injection of 50 g/kg
f dopamine intrarenally is the best means for eliciting
aximal renal hyperemia. In a second study, trans-stenotic
ressure measurements and plasma renin levels were ob-
ained before and after graded stenoses were created in a
tented segment by progressive inflation of a balloon cath-
ter (48). Stenosis severity was expressed as the ratio of
istal pressure (Pd) corrected for aortic pressure (Pa). It was
hown that a Pd /Pa ratio of0.90 determined the threshold
alue below which renin production is increased. Future
tudies will determine whether this level predicts the pres-
nce of renovascular hypertension and whether it predicts
fficacy of stent placement.
ercutaneous heart valves. Cribier et al. (49) reported
heir mid-term results for a study of 36 inoperable patients
ith decompensated congestive heart failure and aortic valve
rea 0.7 cm2 treated with an equine pericardium valve in
balloon-expandable, stainless-steel stent. Twenty-seven
atients had successful implantation with improvement in
alve area (0.60 to 1.70 cm2, p  0.0001) and transvalvular
radient (37 to 9 mm Hg, p  0.0001) and improvement in
V function. Thirty-day major adverse events were 26%.
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Highlights From JACC in 2006 January 30, 2007:509–27leven patients are currently alive with a follow-up of 9
onths. All patients experienced amelioration of symptoms.
ercutaneous heart valve function remained unchanged
uring follow-up, and no deaths were device-related. This
tudy shows the feasibility of this approach in inoperable
atients but also highlights the poor prognosis of such
atients in general.
ontrast nephropathy. The RECOVER (Renal Toxicity
valuation and Comparison Between Visipaque [Iodixanol]
nd Hexabrix [Ioxaglate] in Patients With Renal Insuffi-
iency Undergoing Coronary Angiography) (50) prospec-
ive, randomized trial in 300 patients compared iodixanol, a
onionic, dimeric, iso-osmolar contrast medium (IOCM)
o ioxaglate, a low-osmolar contrast media (LOCM) in
igh-risk patients (creatinine clearance [CrCl] 60 ml/
in). The primary end point, the incidence of contrast-
nduced nephropathy (CIN), was significantly lower with
odixanol than with ioxaglate (7.9% vs. 17.0%; p  0.021).
his randomized controlled trial was corroborated by a
eta-analysis of 2,727 subjects showing similar results (51).
AD
his year, the first in a new class of agents, ranolazine, was
pproved by the FDA for the treatment of stable angina
ymptoms. Although the mechanism of action of ranolazine
s not entirely clear, it might be related to reduction of the
alcium overload that accompanies ischemia as well as heart
ailure and is related to the late sodium channel current.
ne of the pivotal trials that led to FDA approval was
ublished as an expedited review in the Journal (52). The
RICA (Efficacy of Ranolazine in Chronic Angina) trial
as a large (n  565) study of patients with stable angina
ith 3 or more episodes/week despite therapy with amlo-
ipine at 10 mg/day. Subjects were randomized to 1,000 mg
anolazine or placebo twice daily and followed for 6 weeks.
he primary end point, angina frequency, was 5.63 epi-
odes/week at baseline and was reduced in frequency by
anolazine compared with placebo (2.88 vs. 3.31, respec-
ively). Patients with more frequent angina had a more
ronounced treatment effect, and the drug was well toler-
ted without hemodynamic changes. In an accompanying
ditorial Cairns (53) highlighted the potential for dose
elated QTc prolongation with the agent, although there
ave not thus far been any cases reported of torsades.
ndeed, its effects on the late sodium channel current might
ctually decrease early afterdepolarizations (EADs), which
ave been associated with torsades.
Indeed, with the exception of high-risk groups such as
atients with 3-vessel coronary disease and left ventricular
ysfunction, revascularization has not been shown to be
uperior to medical management for stable angina in terms
f survival, although surgical revascularization has been
hown to be superior to medical treatment for eliminating
nginal symptoms. With similar outcomes across treatment
odalities, what is the role then for physician judgment? In cn ingenious prospective substudy of the MASS II (Medi-
ine, Angioplasty, or Surgery Study II) trial, Pereira et al.
54) analyzed the possible role of physician judgment, by
omparing the outcomes of patients who were randomized
o a treatment preferred by 2 experienced physicians (con-
ordant patients) to those randomized to a different treat-
ent (discordant patients). They found that discordant
atients had a worse outcome, driven particularly by those
andomized to PCI. Angiographic variables identified by
he physicians were an important predictor of risk. As
ighlighted in an accompanying editorial (55), these find-
ngs support the role of physician judgment in clinical
ecision making, whether one labels this “the art of medi-
ine” or simply “integration” of data elements that are not
dequately included in our traditional risk stratification
ools.
erioperative risk. The highest-risk patients for perioper-
tive ischemic complications are patients undergoing major
ascular surgery. Poldermans et al. (56), in the second
ulticenter DECREASE-II (Dutch Echocardiographic
ardiac Risk Evaluation) study, randomized 1,476 patients
eceiving beta blockers with 1 to 2 risk factors (older than 70
ears of age, angina, prior MI, heart failure, diabetes treated
ith medication, renal dysfunction, and prior stroke/
ransient ischemic attack [TIA]) to stress-testing versus
nly continued medical therapy before surgery. Although
schemia was documented in 26% of patients randomized to
he stress-testing arm, the incidence of cardiac death or MI
t 30 days after surgery was not improved in the stress-
esting arm. Evidence of adequate beta blockade with a
eart rate of 65 beats/min was associated with lower risk,
rrespective of stress-testing. Obviating stress-testing re-
uced delay to surgery by almost 3 weeks. The authors could
ot exclude a benefit of revascularization in the 8.8% of
atients who had extensive ischemia on noninvasive testing,
ut overall the no stress-test approach seemed reasonable in
he overall population.
ntiplatelet therapy. The treatment of coronary disease,
articularly of unstable disease, employs aggressive
ntiplatelet and antithrombotic therapies. Recently, the
dverse effect of bleeding has received increasing attention.
n a retrospective analysis from the PROTECT–TIMI-30
A Randomized Trial to Evaluate the Relative Protection
gainst Post-PCI Microvascular Dysfunction and Post-
CI Ischemia Among Anti-Platelet and Anti-Thrombotic
gents) trial (57), the TIMI group analyzed predictors of
leeding in patients receiving the glycoprotein IIb/IIIa
nhibitor eptifibatide. The authors found that reduced
reatinine clearance and age were important predictors, with
ge being the independent variable. Age interacted with
enal function in that elderly patients often had reduced
learance but did not have their dose of eptifibatide
djusted.
therosclerosis and lipids. ADIPONECTIN. The complex-
ty of lipid metabolism, inflammation, and their interactions
ontinued to be the focus of much new research in 2006.
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January 30, 2007:509–27 Highlights From JACC in 2006articular attention has been garnered by adiponectin, a
ytokine secreted by adipocytes and purported to have
ntiatherosclerotic, anti-inflammatory, and insulin-sensitizing
ffects (58). Low levels of adiponectin are found in subjects
ith the metabolic syndrome in general and with abdominal
besity in particular. Two studies in 2006 in the Journal
ighlighted the potential importance of adiponectin. Ot-
uka et al. (59) from Japan showed in a study of 207 men
ith CAD that low plasma levels of adiponectin were
ssociated with complexity of angiographic coronary lesions
n both stable CAD and in ACS patients, with ACS
atients having the lowest levels. Therefore, adiponectin
ight play an important role in plaque instability, which is
ssociated with complexity of lesions. As diabetic patients
re at increased risk of ACS, adiponectin might be an
mportant link between diabetes and plaque rupture. In-
eed, in an observational study from Germany, Koenig et al.
60) showed that subjects in the highest tertile of adiponec-
in levels had lower rates of incident type II diabetes and
ncident coronary heart disease. This relationship was no
onger independently significant after adjustment for HDL
holesterol (HDL-C) levels. Importantly, subjects with
oth low adiponectin and low HDL-C levels had a signif-
cantly increased incidence of both diabetes and coronary
isease compared with those with high HDL-C and high
diponectin.
DL. High-density lipoprotein cholesterol itself continues
o be the subject of intense interest, given the known
pidemiologic association of low HDL-C levels and CAD.
wo clinical trials (61,62) of torcetrapib, a novel cholesterol
ster transfer protein (CETP) inhibitor, were published in
he Journal (CETP as a target of therapy was also the subject
f a State-of-the-Art paper [63]). Both trials were 8 weeks
ong and focused on patients with below-average HDL-C
evels. The HDL-C levels increased in a dose-dependent
anner in both trials in the presence of background
torvastatin therapy. Low-density lipoprotein cholesterol
LDL-C) levels decreased further beyond the levels seen
ith atorvastatin monotherapy. The HDL-C level increases
ere impressive: up to 54.5% in the monotherapy study and
0.2% with atorvastatin. As commented upon in an accom-
anying editorial (64), whether these HDL-C changes are
ssociated with reduced atherosclerosis and clinical events
uch as MI can only be determined from longer-term
andomized trials. Indeed, shortly after the publication of
hese 2 studies, the torcetrapib program was halted by its
anufacturer, Pfizer Inc., due to a surprising increase in
ardiovascular events in a long-term trial of the drug,
ighlighting yet again the importance of actual outcome
tudies as opposed to surrogate end points.
High-density lipoprotein cholesterol is a complex li-
oprotein with both anti-inflammatory and pro-
nflammatory properties. Dietary influences might affect
DL-C functionality, an issue that was highlighted in atudy (65) of 14 subjects given either a saturated or aolyunsaturated meal on 2 occasions. After the ingestion of
saturated fatty meal, HDL-C was less effective in inhib-
ting the expression of the inflammatory mediators
CAM-1 and VCAM-1 in isolated endothelial cells. En-
othelial function as assessed by flow-mediated dilation was
lso adversely affected by the saturated fat meal. The
DL-C might also be made more pro-inflammatory and
ro-atherogenic in the presence of elevated myeloperoxidase
evels, a hemoprotein with antimicrobial properties. Indeed,
n a large prospective study of carotid atherosclerosis (66),
levated myeloperoxidase levels were associated with pro-
ression of disease but only in patients with HDL levels
elow 49 mg/dl.
tudies in patients with heart failure and/or LV dys-
unction. POLYUNSATURATED FATTY ACID AND BARORE-
LEX CONTROL. Although data exist that polyunsaturated
atty acids (PUFA) have anti-arrhythmic effects in post-MI
atients, the mechanism involved has remained uncertain.
adaelli et al. (67) carefully studied a group of patients with
ost-MI LV dysfunction to determine whether PUFA
reatment enhances baroreflex control in patients with
ost-MI LV dysfunction. In the study, baroreflexes were
ssessed from responses to neck suction (NS) and by
omputation of the alpha spontaneous baroreflex sensitivity
ndex at baseline and 4 months of treatment with 2 g/day
UFA or placebo. Both reflex depressor and bradycardic
esponses to NS increased after PUFA but not placebo, as
id spontaneous baroreflex sensitivity, R-R interval vari-
nce, and low- and high-frequency spectral powers. These
esults indicate that, in post-MI patients with LV dysfunc-
ion, treatment with PUFA markedly potentiates baroreflex
unction and enhances heart variability, which might ex-
lain the favorable effects of PUFA treatment on ventricular
rrhythmias.
F IN HEART FAILURE WITH/WITHOUT SYSTOLIC DYSFUNC-
ION. Although AF is the most common arrhythmia in
eart failure, virtually all information regarding the preva-
ence, incidence, and effect of AF on prognosis comes from
opulations with systolic dysfunction. Consequently, Ols-
on et al. (68) assessed these issues in patients included in
he CHARM (Candesartan in Heart failure-Assessment of
eduction in Mortality and morbidity) program, which
ncluded populations with a broad range of ejection frac-
ions (EFs), including a large number with an EF 40%
hat were followed in the CHARM-Preserved study. They
ound that baseline incidence was nearly the same in
atients with heart failure and EF 40% as in patients with
ow EF (19% compared with 17%). Although AF was
redictive of a high risk of cardiovascular mortality and
orbidity in both groups, it was associated with greater
elative increased risk of major cardiovascular outcomes in
atients with preserved EF. During the study, new-onset
F occurred in 7.8% of the low EF group and in 4.9% of the
opulation with an EF40%. Although the absolute risk of
n adverse cardiovascular outcome was highest in the low
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Highlights From JACC in 2006 January 30, 2007:509–27F new-onset AF patient group, the patients with EF
40% had a significantly greater relative increase in risk.
he presence of AF did not alter candesartan effects in the
HARM study population. These results point out both
he high prevalence of AF in heart failure patients with or
ithout systolic dysfunction and suggest that relative risk for
dverse cardiovascular outcomes might be greater in the
opulation with an EF 40%, further debunking the
oncept that heart failure with preserved EF has a consid-
rably better prognosis.
O BENEFICIAL EFFECTS OF STATINS IN HEART FAILURE
XTEND BEYOND THEIR ABILITY TO LOWER LIPIDS? Con-
roversy continues regarding whether statins might benefit
eart failure through mechanisms other than reducing
DL-C and acute coronary events. Sola et al. (69) examined
he effects of statin therapy on vascular markers of inflam-
ation and echocardiographic parameters of LV structure
nd function in patients with nonischemic cardiomyopathy.
hey randomized 108 patients with LVEF 0.35 in a
ouble-blinded fashion to receive either atorvastatin 20
g/day or placebo in addition to standard heart failure
herapy. Whereas LVEF tended to decrease and end-
iastolic dimension (EDD) and end-systolic dimension
ESD) increased in the placebo group, EF increased 33% to
7%, (p  0.01), EDD decreased 57.1 to 53.4 mm (p 
.02), and ESD decreased 42.4 to 39.1 mm, (p  0.007)
ith atorvastatin. The atorvastatin-induced increase in
rthrocyte superoxide dismutase and decrease in C-reactive
rotein (CRP) and interleukin-6 suggested that statins
mprove cardiac function by reducing inflammation.
In contrast to these favorable results of statin therapy,
leske et al. (70) found in a small group of nonischemic
ardiomyopathy patients with average LDL-C levels that 12
eeks of 80 mg/day atorvastatin did not alter levels of
iomarkers that reflected cardiac remodeling, endothelial
ell function, and inflammation compared with placebo. In
n editorial comment, Ramasubbu and Mann (71) theorized
hat the somewhat discrepant findings were due to the
elatively small size and the differences in baseline charac-
eristics of patients in the 2 studies. In particular, they noted
hat the population in the negative study by Bleske et al.
70) had minimal activation of neurohormonal and inflam-
atory systems, in which case “one might not have expected
o have observed striking changes in the panel of biomarkers
ollowing statin treatment.” The editorial concluded that,
lthough statins should be used in patients with heart failure
ho have elevated LDL levels and known coronary disease,
he use of these agents in nonischemic patients remains
nanswered.
NTERSTITIAL MATRIX REMODELING IN HEART FAILURE.
bnormalities in the extent and distribution of collagen
ithin the remodeling heart have been recognized as play-
ng an important role in the pathogenesis of heart failure.
opez et al. (72) assessed the distribution of collagen
eposits and collagen degradation in endomyocardial biopsy cpecimens from 39 hypertensive patients with either systolic
eart failure (SHF) or diastolic heart failure (DHF). They
ound that mysial collagen that is related to muscle com-
artments was reduced in SHF patients but that perivascu-
ar and scar related collagen volumes were higher in both
HF and DHF hypertensive patients than in normotensive
ubjects and in SHF compared with DHF patients. Activity
f matrix metalloproteinases (MMPs) (involved in collagen
egradation), assessed as the ratio of MMP-1 to its tissue
nhibitor (TIMP)-1, was increased in the SHF hypertensive
roup compared with control subjects and DHF patients.
he MMP-1 expression was increased in the interstitium
nd in cardiomyocytes of SHF compared with both hyper-
ensive and normotensive DHF patients. Moreover, the
MP-1/TIMP-1 ratio was significantly correlated with EF
n an inverse manner, and it correlated directly with LV
nd-diastolic diameter. Thus, patterns of collagen deposi-
ion differ between SHF and DHF, suggesting that there is
n association between the breakdown of mysial collagen
nd the development of SHF in hypertensive patients. The
esults also implicate alterations in the balance of the
MP/TIMP system in this process. As noted in an
ccompanying editorial by Shirwany and Weber (73), these
ndings raise the prospect that serum measurements of
MP and TIMP levels could be used to detect abnormal-
ties in the interstitial matrix of the heart that could account
or ventricular remodeling and dysfunction in hypertensive
atients and that such markers might also serve to monitor
nterventions designed to alter the remodeling process.
On the basis of substantial evidence that MMPs are
ctivated in the post-MI heart where they seem to play a
ole in interstitial matrix remodeling, Hudson et al. (74)
tudied the effects of the MMP inhibitor PG-116800 on
ost-MI cardiac remodeling. In the study, 253 patients with
first ST-segment elevation MI and reduced EF were
nrolled within 48 h of the MI and randomized to either
ctive drug or placebo treatment for 90 days. The results
howed that MMP inhibition with PG-116800 did not
ignificantly alter LV volumes, sphericity index, EF, or rates
f death or recurrent MI. There was an increase in the
ncidence of arthralgia and joint stiffness. These results
uggest that MMP inhibition after MI might not be an
ffective way to alter LV remodeling.
Fragasso et al. (75) published a randomized clinical trial
f trimetazidine, a partial free fatty acid oxidation inhibitor,
n patients with heart failure. In this study 55 patients with
ongestive heart failure were allocated to conventional
herapy plus trimetazidine or conventional therapy alone. At
tudy entry and follow up, patients underwent exercise
esting and 2-dimensional echocardiography. The findings
emonstrated that patients taking trimetazidine had im-
rovement in New York Heart Association functional class,
xercise tolerance, quality of life, and LV function. They
lso used fewer diuretic agents and digoxin and had lower
-type natriuretic peptide (BNP) levels. The authors con-
luded that the concept of shifting the energy substrate
p
g
t
n
r
d
a
p
l
w
u
c
H
r
p
r
i
i
b
a
b
m
M
m
i
t
0
m
s
d
J
D
t
I
N
o
m
c
n
I
s
r
c
c
t
f
s
p
Q
o
s
n
p
t
p
(
t
c
o
a
c
w
p
u
p
a
i
t
f
c
a
m
l
u
p
fi
w
a
4
M
e
i
w
H
s
i
o
p
2
0
i
n
b
m
t
S
o
l
a
U
d
a
i
r
P
p
a
517JACC Vol. 49, No. 4, 2007 DeMaria et al.
January 30, 2007:509–27 Highlights From JACC in 2006reference away from fatty acid metabolism and toward
lucose metabolism by trimetazidine is an effective adjunc-
ive treatment in patients with heart failure. The accompa-
ying editorial by Wilson Tang (76) notes that the study
aises an important conceptual question about developing
rugs for heart failure therapy. The prerequisite for drug
pproval in the U.S. mandates demonstration of hard end
oints such as mortality in large clinical trials, even for drugs
ike trimetazidine that have already been demonstrated to be
ell tolerated. The high barrier for approval makes it
nlikely that trimetazidine will be approved for treating
ongestive heart failure in the near future.
eart rhythm disorders. DEFIBRILLATOR THERAPY. The
ole of implanted cardioverter-defibrillator (ICD) therapy in
revention of sudden death has been an important topic
ecently. Two papers in the Journal in 2006 addressed the
ssue of timing of ICD implantation in patients with
schemic and nonischemic cardiomyopathy. The first article,
y Goldenberg et al. (77), evaluated 951 patients in whom
coronary revascularization (CR) procedure was performed
efore enrollment in the MADIT-II (Multicenter Auto-
atic Defibrillator Implantation Trial). This substudy of
ADIT-II showed that in patients enrolled more than 6
onths after coronary revascularization there was a signif-
cant survival benefit of ICD implantation versus conven-
ional medical therapy (all cause mortality HR 0.64, p 
.01). There was no benefit in those enrolled within 6
onths of revascularization, probably owing to a low risk of
udden cardiac death and a higher risk of nonarrhythmic
eath in this group. In a similar article published in the
ournal, Kadish et al. (78) evaluated the 458 enrolled in the
EFINITE (Defibrillators in Nonischemic Cardiomyopa-
hy Treatment Evaluation) trial for an effect of timing of
CD implantation on survival. This substudy of DEFI-
ITE analyzed the survival benefit of therapy on the basis
f time from diagnosis. Patients receiving an ICD within 3
onths of diagnosis had improved survival (p  0.05)
ompared with conventional therapy, with borderline sig-
ificant improvement (p  0.058) in those receiving an
CD within 9 months of diagnosis. Thus, this study
uggests that nonischemic cardiomyopathy patients should
eceive an ICD early after diagnosis, because the benefit
onferred is not time dependent.
Some degree of controversy has surrounded the issue of
ardiac resynchronization therapy (CRT) with respect to
he necessity of additional defibrillator therapy in heart
ailure patients without prior ventricular arrhythmias. A
tudy by Ypenburg et al. (79) addressed this issue in 191
atients with advanced heart failure, LVEF 35%, and
RS duration120 ms. Seventy-one patients had a history
f ventricular arrhythmias and were designated as the
econdary prevention group, whereas 120 patients who had
o history of ventricular arrhythmias were designated as the
rimary prevention group. During 18 months of follow-up
he primary prevention patients experienced fewer appro-
riate ICD therapies than the secondary prevention group c21% vs. 35%, p  0.05). However, no predictors of ICD
herapy could be identified on multivariate analysis. Similar
linical improvement was observed in both groups, and the
verall mortality rate was less in the primary versus second-
ry prevention group (3% vs. 18%, p  0.05). The authors
oncluded that, because the appropriate ICD therapy rate
as so high (i.e., 21%) in the primary prevention group, all
atients with congestive heart failure and reduced LVEF
ndergoing CRT should have a CRT-ICD device im-
lanted as opposed to a CRT-only device. The authors
cknowledge that the small study size might have precluded
dentification of predictors of appropriate ICD therapy and
hat ICD therapy might not have been a definitive surrogate
or mortality.
Risk stratification of patients to improve selection of
andidates for ICD implantation has been an important
rea of research, both to reduce unnecessary implants and to
anage spiraling costs. Two important articles were pub-
ished in the Journal in 2006 providing evidence in favor of
sing microvolt T-wave alternans (MTWA) to risk stratify
atients for potential lethal ventricular arrhythmias. The
rst study, by Bloomfield et al. (80), evaluated 549 patients,
ith LVEF 40% and no history of sustained ventricular
rrhythmias (SVA). Ischemic heart disease was present in
9%, mean LVEF was 25%, and 66% had abnormal
TWA. During 20 months’ follow-up, 40 deaths and 11
pisodes of nonfatal SVA occurred (2.5% 2-year event rate
n patients without abnormal MTWA and 15% in patients
ith abnormal MTWA). The MTWA tests resulted in an
R for the primary end point of 6.5 at 2 years. In a similar
tudy, Chow et al. (81) showed, in 768 patients with
schemic cardiomyopathy and LVEF 35% and no history
f SVA, that a non-negative MTWA test (observed in 514
atients, 67%) was associated with a higher all-cause (HR
.24, p  0.002) and arrhythmic mortality (HR 2.29, p 
.049). An area of controversy has been the value of an
ndeterminate MTWA test (i.e., neither negative nor non-
egative). Both this study by Chow et al. (81) and another
y Kaufman et al. (82) demonstrated an increased risk of
ortality and nonfatal SVA events in patients with inde-
erminate MTWA tests.
UDDEN DEATH. With respect to other possible predictors
f sudden death in the general population, 2 studies pub-
ished in the Journal in 2006 are of significance. Stecker et
l. (83) reported 2-year findings from the Oregon Sudden
nexpected Death Study where all cases of sudden cardiac
eath (SCD) occurring in 1 county were analyzed clinically
nd demographically from available records. This study
ncluded 704 cases of SCD. The LVEF was severely
educed in 30% and mildly to moderately reduced in 22%.
atients with normal LVEF were younger, with a higher
roportion of women, higher prevalence of seizure disorder,
nd lower prevalence of established CAD. The authors
oncluded that only one-third of SCD cases had severely
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Highlights From JACC in 2006 January 30, 2007:509–27educed LVEF and met criteria for ICD implantation,
uggesting a need for development of alternative screening
ethods to enhance identification of patients at risk for
CD in the general population. One possible risk factor that
ould be screened in this manner was suggested by Strauss
t al. (84) in a prospective, population-based cohort study
omprising 3,105 men and 4,878 women ages 55 years and
lder as part of the Rotterdam Study. The authors evaluated
he QTc interval on electrocardiography obtained in pa-
ients at baseline visit (1990 to 1993) and their first
ollow-up visit (1993 to 1995) and determined that over an
verage follow-up period of 6.7 years in the 125 patients
hat died suddenly, a prolonged QTc interval (450 in men
nd470 in women) was associated with a 3-fold increased
isk of SCD (HR 2.5) overall and an 8-fold increased risk of
CD in those patients younger than the median age of 68
ears.
No medical therapy has previously been shown to have a
ignificant positive impact upon SCD. Recently, statin
herapy has been shown to at least reduce the risk of SCD
n 2 studies reported in the Journal. In the first study,
ublished by Vyas et al. (85), statin use was evaluated in 654
atients receiving ICDs as part of the MADIT-II study.
he patients were categorized by percentage days of statin
se. The results showed that the cumulative rate of ICD
herapy for ventricular tachycardia/ventricular fibrillation or
ardiac death was significantly reduced in those with 90%
tatin use compared with those with lower statin use (p 
.01). The time-dependent statin/no statin therapy HRs
ere 0.65. In a similar study, published by Goldberger et al.
86), they reported in 458 patients enrolled in the DEFI-
ITE study that those on statin therapy had a reduced
verall death rate (HR 0.22, p  0.0001), reduced arrhyth-
ic sudden death rate (HR 0.16, p  0.08), and reduced
ate of appropriate ICD shocks (HR 0.78). The authors of
hese studies suggest that statins have an antiarrhythmic
ffect, although the mechanism—either a direct or indirect
ffect—is unknown.
F. Significant advances in the treatment of AF have also
een made in recent years, particularly curative catheter
blation procedures. Catheter ablation has been suggested
ot only to be cost effective as a treatment compared with
edical therapy but also to reduce morbidity and mortality,
articularly in patients with congestive heart failure. The
ptimal approach to ablation of AF has not been proven,
owever. One study published in the Journal by Calo et al.
87) suggest that more extensive ablation, including both
he right and left atria, might improve results with lower
ecurrence rates of AF. During 14  5 months follow-up,
F recurred in 39% of patients in the LA ablation group but
n only 15% of patients in the biatrial ablation group (p 
.022), multivariable Cox regression analysis showed abla-
ion technique to be an independent predictor of AF
ecurrence during follow-up. iWith regard to the impact on outcomes of treatment,
here is increasing evidence that maintenance of sinus
hythm has advantages over persistence of AF. Singh et al.
88) published a substudy, derived from the larger Veterans
ffairs cooperative study (SAFE-T), in which AF patients
ere randomized to antiarrhythmic drugs amiodarone, so-
alol, or placebo, and after 28 days they were cardioverted if
ot in sinus rhythm and followed for up to 1 year. In this
ubstudy, patients’ quality-of-life scores and exercise capac-
ty were analyzed by outcome at 8 weeks and 1 year. Patients
emaining in sinus rhythm at 8 weeks had significantly
etter physical functioning (p  0.03), physical role limita-
ions (p  0.03), general health (p  0.002), vitality (p 
.001), and at 1 year better general health (p  0.007) and
ocial functioning (p  0.02) compared with AF. Patients
emaining in sinus rhythm had better symptom checklist
everity scores (p  0.01), functional capacity, and AF
everity scale symptom burden at 8 weeks and in symptom
hecklist severity scores (p  0.01) and AF severity scale
ymptom burden at 1 year. Exercise performance was better
n sinus rhythm versus AF at 8 weeks and at 1 year. Thus,
estoration and maintenance of sinus rhythm compared
ith AF resulted in improvement in quality of life and
xercise performance both short-term and long-term in this
tudy.
Although rate control with antiarrhythmic drugs and
trioventricular (AV) node ablation have both been shown
o increase LVEF in some patients with AF and depressed
V function, a recent study published by Gasparini et al.
89) in the Journal suggested that, in patients with conges-
ive heart failure undergoing CRT, only those undergoing
V junction ablation derived benefit. Within the AF group,
uring a mean follow-up of 25.2 months, only patients
ndergoing AV junction ablation showed an increased
VEF (p  0.001), reverse remodeling effect (p  0.001),
nd improved exercise tolerance (p  0.001), whereas no
mprovements were observed in AF patients who did not
ndergo ablation. These data are supported by another
tudy published in the Journal by Hayes et al. (90), a
ub-group analysis of the DAVID (Dual Chamber and VVI
mplantable Defibrillator) trial, in which the effects of QRS
uration on outcome was analyzed in patients undergoing
CD implantation with the device programmed to avoid
VVI-40) or produce more frequent ventricular pacing
DDDR-70). The DAVID trial showed that patients with
ubstantial ventricular pacing (right ventricular) have an
ncreased risk of a combined end point of death and new or
orsening congestive heart failure. This substudy evaluated
he effects of pre-existing QRS duration on outcomes.
here was a significantly higher risk of developing the
ombined end point of death or congestive heart failure in
he group with more ventricular pacing (DDDR-70) and an
bnormal QRS duration, but the QRS duration had no
ffect on outcome in the minimal ventricular pacing group
VVI-40). This study, as noted by the authors, should not
mply that right ventricular pacing is safe in patients with
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January 30, 2007:509–27 Highlights From JACC in 2006ormal QRS duration but rather suggests that right ven-
ricular pacing should be avoided in patients with pre-
xisting abnormal QRS duration. A further interpretation,
lso suggested by other studies, is that if ventricular pacing
s necessary because of AV conduction disturbance, then
iventricular pacing should be considered in patients with
re-existing abnormal QRS duration.
uclear, cardiac magnetic resonance, and CT imag-
ng. CARDIAC CT. A study by Leber et al. (91) reports on
0 patients in whom 64-slice CT was compared with IVUS
o assess plaque morphology and composition. Although
nly moderate correlation was observed between plaque size
y the 2 methods, the authors found significant agreement
n classifying lesions as calcified, noncalcified, or mixed.
hey concluded that “64-slice CT reveals encouraging
esults to noninvasively detect different types of coronary
laques located in the proximal coronary system. The ability
o determine plaque burden currently is hampered mainly by
n insufficient reproducibility.”
Another article reported a meta-analysis of the published
ata comparing multi-director CT angiography (MDCTA)
nd invasive angiography, which included single and multi-
enter trials with 16-, 32-, and 64-slice MDCT. Hamon et
l. (92) included 29 studies reporting on 2,024 patients’
yndromes referred for coronary angiography mostly with
hest pain. The per-segment sensitivity and specificity were
1% (95% confidence interval [CI] 72% to 89%) and 93%
95% CI 90% to 97%), respectively, whereas the per-patient
ensitivity and specificity were 96% (95% CI 94% to 98%)
nd 74% (95% CI 65% to 84%), respectively. Although at
he segment level the difference between 16 to 64
DCTA only showed a trend of borderline significance,
n a per-patient analysis basis 64-MDCTA was superior
p  0.026).
An article by Hausleiter et al. (93) examined the preva-
ence of noncalcified coronary plaques by 64-slice CT in
atients with an intermediate risk for significant CAD.
oncalcified coronary plaques were detected in 48 (29.8%)
f 161 patients examined by MDCTA. The prevalence of
oncalcified plaques as the only manifestation of CAD was
.2% (10 of 161 patients), whereas in 60 of the 161 (37.3%)
nly calcified plaques were present. The authors concluded
hat “with the use of 64-slice CT, clearly discernible
oncalcified atherosclerotic coronary plaques can be de-
ected in a large group of patients with an intermediate risk
or having CAD.”
Several studies focused on the application of coronary
DCTA in specific patient groups. Limitations exist to the
ccurate identification of coronary stenoses in patients with
eft bundle branch block (LBBB). Ghostine et al. (94)
erformed MDCTA in 66 LBBBB patients undergoing
tandard angiography and observed a sensitivity and speci-
city of 97% and 95%. In an accompanying editorial,
skandrian (95) comments that, despite the favorable data, it
s premature to conclude that MDCTA will be the diag-
ostic procedure of choice for LBBB patients. Another sbvious niche application for MDCTA is in the preopera-
ive evaluation of coronary disease in valve disease patients.
ilard et al. (96) performed 16-slice MDCTA in 55
reoperative aortic stenosis patients. The positive and neg-
tive predictive valve of MDCT compared with standard
ngiography was 55% and 100%, which would have enabled
nvasive angiography to be avoided in 805 patients with an
gaston score 1,000. In an editorial, Hoffman et al. (97)
ointed out that the use of MDCTA for this application
ill depend greatly upon the prevalence of disease and
oronary calcification and that more data will be required.
In combination with vessel imaging, MDCT has signif-
cant potential as a technology that could assess myocardial
erfusion, function, and viability. In preclinical studies,
aks et al. (98) and George et al. (99) used MDCTA to
easure infarct size and stress perfusion, respectively. In the
rst study, the authors document the ability of MDCTA to
ccurately quantify MI relative to delayed enhanced MRI as
he gold-standard technique. In the second, the authors
emonstrate the ability to combine coronary angiography
nd stress perfusion induced by intravenous adenosine in
nimals with artificially induced left anterior descending
tenoses. Myocardial blood flow and perfusion defects
orrelated well with microsphere blood flow and other
istopathologic techniques, demonstrating the potential of
ombining coronary angiography with stress perfusion dur-
ng a single MDCT data acquisition.
ARDIOVASCULAR MRI. The power of MRI to phenotype
ardiovascular disease, particularly in large population stud-
es, was exemplified by Barbier et al. (100), who examined
he prevalence of “silent” myocardial scars in 259 randomly
elected 70-year-old individuals in Sweden. Although scars
onsistent with MI were found in 60 study participants
24.2%), they reflected clinically silent episodes in 49
19.8%) of them. However, the volumes of previously
nidentified scars were significantly smaller than those
eflecting clinically manifested infarction. In another
hought-provoking population research study from the
ESA (Multi-Ethnic Study on Atherosclerosis) trial,
ang et al. (101) examined the relationship between
picardial coronary atherosclerosis characterized by calcium
cores and regional myocardial perfusion studied by contrast
nhanced MRI at rest and during adenosine infusion. A
otal of 222 MESA participants, ages 45 to 84 years and free
f past clinical cardiac disease, were enrolled in this study
hat demonstrated that “coronary vasodilatory response was
ssociated inversely with the presence and severity of CAC
n asymptomatic adults.” A third research study, using MRI
o phenotype cardiovascular disease in the MESA popula-
ion of asymptomatic adults, related carotid atherosclerosis
o regional myocardial function measured by MR tissue
agging. In this report by Fernandes et al. (102) greater
therosclerosis was associated with reduced myocardial
unction measured as the magnitude of circumferential
hortening in the lateral, posterior, and septal walls, whereas
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Highlights From JACC in 2006 January 30, 2007:509–27iastolic function assessed as strain rate during early filling
as decreased even after adjustment for age and other
ariables. The common theme of these studies was the
ocumentation of cardiac involvement manifested as dys-
unction, perfusion reserve, and fibrosis as detected by MRI
arlier or to a greater extent than previously suspected.
Journal cardiovascular MRI highlights also included stud-
es using delayed enhancement to predict response to
ardiac resynchronization. Thus, White et al. (103) studied
3 patients with QRS duration 120 ms and dyssynchrony
nd found that a percent total scar of 15% yielded a
ensitivity of 85% and specificity of 90% in predicting
esponse to CRT. State-of-the-art coronary magnetic res-
nance angiography (MRA) with novel “whole heart” ac-
uisition techniques was reported by Sakuma et al. (104).
ree breathing whole heart coronary angiography was fea-
ible in 86% of 113 patients and yielded a patient-based
ensitivity of 82% and specificity of 90%.
Finally, the recently recognized potential of noninvasive
RI to provide unique prognostic information in terms of
isk for sudden death and malignant ventricular remodeling
s reflected in 2 studies focusing on patients with chronic
yocarditis by De Cobelli et al. (105) and in patients with
ilated cardiomyopathy by Assomull et al. (106). In the
atter study, the pattern of midwall fibrosis as defined by
ontrast-enhanced MRI related to all-cause mortality and
ardiovascular hospitalization independent of ventricular
emodeling. As the authors remarked, “this suggests a
otential role for CMR in the risk stratification of patients
ith dilated cardiomyopathy.”
OSITRON EMISSION TOMOGRAPHY (PET)/CT. Several stud-
es using PET/CT to examine diverse aspects of cardiovas-
ular pathophysiology appeared in the Journal this year.
mong those, the study by Yoshinaga et al. (107) investi-
ated the prognostic significance of alterations in myocar-
ial perfusion quantified by Rubidium-82 PET in 367
atients who underwent dipyridamole 82Rb PET myocar-
ial perfusion imaging (MPI). The annual hard events rates
ere 0.4%, 2.3%, and 7.0% in 3 groups of patients classified
s normal, mild, and moderate-severe in terms of a summed
tress score. Moreover, in adjusted survival models, 82Rb
ET summed stress scores were the strongest predictors of
otal cardiac events and also a predictor of hard events,
howing that 82Rb PET has significant prognostic power in
atients with heart disease.
In another study focused on exploring the ability of
integrated PET/CT to dissect cardiovascular biologic
echanisms from gene expression to physiologic function
nd morphology” Wagner et al. (108) investigated regional
ngiogenesis in a model of local adenovirus transfer of the
EGF121 gene to myocardium of healthy pigs. They doc-
mented successful transgene expression 2 days after gene
ransfer by a reporter probe targeting co-expressed HSV1-sr39tk
eporter gene. Increased local myocardial perfusion was
dentified in areas overexpressing VEGF, corroborating in pivo effects of microvascular tone and permeability. This
legant study documents the enormous potential of these
olecular imaging techniques to probe the most basic
echanisms of myocyte and endothelial cell physiology
nd dysfunction secondary to diverse fundamental disease
echanisms.
eneral Cardiology
iomarkers. It would be useful to find markers to identify
therosclerotic plaques that are prone to rupture. A novel
andidate is pregnancy-associated plasma protein-A
PAPP-A), a zinc-binding matrix metalloproteinase used in
renatal screening. Elevated levels of PAPP-A occur in
AD and are associated with adverse cardiovascular events
n ACS. Sangiorgi et al. (109) extended this observation
rom coronary to carotid atherosclerotic disease. Carotid
ndarterectomy specimens from 72 patients with stroke,
ransient ischemic attack, or no symptoms were character-
zed on the basis of histological examination. When com-
ared with stable plaques, vulnerable and ruptured athero-
clerotic plaques had thin caps with inflammatory infiltrates
ith PPAP-A expression that colocalized with monocytes
nd macrophages by immunostaining. Circulating plasma
evels of PPAP-A were higher in patients with vulnerable
nd ruptured plaques, suggesting that PPAP-A might be a
seful biomarker to identify unstable carotid atherosclerotic
isease. Future studies are needed to determine whether
PAP-A can identify high-risk patients before the onset of
ymptoms and/or predict clinical outcomes.
Waxman et al. (110) studied the ability of the first
roponin I measurement sent from the emergency depart-
ent to be a predictor of all-cause mortality. They devel-
ped a model from data at a single center and then validated
t in another. They demonstrated that in a heterogeneous
opulation of acutely ill patients, the presence of troponin I,
ven at levels below the 99th percentile, is associated with an
ncreased risk for mortality. Mortality risk varied in direct
roportion to order-of-magnitude changes in troponin I,
ore than doubling with any 10-fold increase. The authors
uggest that current recommendations for diagnostic cutoffs
nd for the central role that any single cutoff assumes in the
iagnosis of MI merit reconsideration. In an accompanying
ditorial, Jaffe (111) points out that structural heart disease
an also be responsible for detectable values both below and
bove the putative 99th percentile. Data from a number of
tudies suggest that cardiac troponin, in addition to helping
iagnose acute cardiovascular disease, might also be a more
hronic risk marker. He therefore advocates more sensitive
roponin assays, despite complaints from clinicians who are
rustrated by the inability to find a reason for a high
roponin in some patients. It is the clinicians who must
ducate themselves about the new assays and become
omfortable in how to interpret them.
atriuretic peptides. Tsutamoto et al. (112) measured thelasma BNP level in the aortic root (AO) and coronary
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January 30, 2007:509–27 Highlights From JACC in 2006inus (CS) in 366 consecutive patients with heart failure.
hey observed that hemodynamic parameters such as LV
jection fraction (LVEF) and LV end-diastolic pressure
LVEDP) but not estimated glomerular filtration rate
eGFR) were independent predictors of a transcardiac
ncrease (CS-AO) in BNP; however, the BNP level in the
O was predicted by eGFR (p  0.0001) in addition to
VEF and LVEDP. These findings suggested that BNP
ecretion is not affected by renal dysfunction, whereas BNP
learance is, and that decreased clearance from the kidney
ontributes to the elevated BNP in heart failure patients
ith renal dysfunction.
Schnabel et al. (113) evaluated the role of BNP in 1,085
table angina patients, from AtheroGene study, in predict-
ng cardiovascular events during a long-term follow-up of
.5 years. The BNP concentrations were significantly ele-
ated in patients with future cardiovascular events (median
19.2 pg/ml) compared with those who remained event-free
36.2 pg/ml; p  0.001). These data demonstrated that
NP is a strong predictor of cardiovascular risk in stable
ngina independent of LV systolic performance and known
isk factors.
ypertension. Rossi et al. (114) prospectively investigated
he prevalence of curable forms of primary aldosteronism
PA) in newly diagnosed hypertensive patients. Patients in
4 centers underwent a diagnostic protocol that consisted of
4-h urine and serum for sodium and potassium, seated
lasma renin activity, and aldosterone at baseline and after
0 mg of captopril. Patients with an aldosterone/renin ratio
40 baseline and/or30 after captopril underwent imaging
ests and adrenal vein sampling or adrenocortical scintigra-
hy. An aldosterone-producing adenoma was diagnosed in
atients who in addition to excess aldosterone secretion
howed lateralized secretion of aldosterone, adenoma at
urgery and pathology, and a blood pressure fall after
drenalectomy. Evidence of autonomous aldosterone secre-
ion without such criteria led to a diagnosis of idiopathic
yperaldosteronism (IHA). The authors found that almost
% of newly diagnosed hypertensive patients referred to
pecialized centers for hypertension have a surgically curable
ldosterone-producing tumor. An additional 6.3% had id-
opathic hyperaldosteronism, giving an overall prevalence of
rimary aldosteronism of 11.2%. This clearly warrants
creening in newly diagnosed hypertensive patients. The
iochemical identification of primary aldosterone represents
compelling indication for the search of a unilateral adrenal
ause of aldosterone excess, which is feasible with adrenal
ein sample and is felt to be mandatory by the authors
efore undertaking adrenalectomy.
ongenital Heart Disease
mong the most interesting areas related to pediatric and
dult congenital heart disease and congenital heart sur-
ery are those discussed in two articles related to new
nterventional methods— one that might revolutionize dranscatheter atrial septal defect (ASD) and patent fora-
en ovale closure, and the other related to covered stents
or aortic coarctation and recoarctation.
nterventional methods. A study by Jux et al. (115)
eported the availability of a method to occlude the atrial
eptum while maintaining the normal shape and mechan-
cs of the septum without cumbersome foreign bodies, an
mportant development given the limitations of the
opularly used devices. The BioSTAR device, by NMT
edical, Inc. (Boston, Massachusetts) in conjunction
ith Organogenesis (Canton, Massachusetts), provides a
ioremodelable collagen matrix instead of a fabric scaf-
old. The device is coated with heparin. The experimental
tudy reported placement of the BioSTAR or STARFlex
evices in 36 sheep under fluoroscopy and guided by
ntracardiac echocardiography. Animals underwent intra-
ardiac imaging to detect any residual shunting and were
acrificed at various time points. The ASD closure of
hese medium size defects was excellent. The BioSTAR
howed less deposition of blood-derived materials than
TARFlex. The BioSTAR occluder showed greater cov-
rage with tissue and was completely reabsorbed by 2
ears. This study represents an important chronic animal
tudy as proof of concept.
Tzifa et al. (116) published an interesting multicenter
tudy of a new platinum-covered stent for treatment of
ortic coarctation. They reported 30 patients, 16 of
hom had previous procedures, and 12 of whom had
tent-related complications including fractures, aneu-
ysms, and in-stent thrombosis. Thirty-three covered
tents were implanted into 30 patients, with stent fracture
ccurring acutely in 6 patients, 1 of which was treated
ith implantation of a separate stent. One patient had a
mall subrenal aortic dissection that resolved; in 4 pa-
ients the stents were redilated. Follow-up imaging
howed good position of the stents. Nine of 21 patients
ad some reduction of their hypertension medication.
he study confirms early and intermediate results with
he use of the platinum-covered stent as a rescue method.
ongenital heart surgery. A report by Li et al. (117)
ddresses the precarious hemodynamics and pharmaco-
ogic management that occurs in infants with hypoplastic
eft heart syndrome after first-stage Norwood, where
esistances and pressures in the pulmonary and arterial
irculation, cardiac work, and oxygenation need to be
alanced. Thirteen sedated, paralyzed, and ventilated
eonates were followed for 72 h after the Norwood
rocedure; systemic and pulmonary blood flows were
alculated. Oxygen extraction, a rate/pressure product,
nd systemic oxygen consumption were also obtained.
opamine was administered at 5 g/kg in 12 patients
nd 7.5 g/kg in the rest and terminated within the first
8 h in all patients. Dopamine was shown in this study to
ave adverse effects both on carbon dioxide and oxygen
elivery. The adrenogenic receptor stimulation of the
rug increased metabolic rate. Termination of the dopa-
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Highlights From JACC in 2006 January 30, 2007:509–27ine did not specifically change pressures or Q p/Q s but
ecreased heart rate and rate pressure product as well as
ecreasing oxygen extraction ratio. The study suggests
hat care must be taken regarding circulatory support of
hese neonates after cardiopulmonary bypass and the
mportance of understanding changes in oxygen use and
elivery in critically ill neonates after the Norwood
rocedure.
An important study looked at long-range outcomes of
ulmonary valve and proximal pulmonary artery inter-
osed into the aortic position during arterial switch. This
rticle from Losay et al. (118) reported follow-up data on
,156 hospital survivors operated on between 1982 and
000 with the follow-up data up to 7 years; 14.9% had
ignificant aortic regurgitation at last follow-up, which
as associated with complex transposition, prior pulmo-
ary banding, aortic arch anomalies, older age at arterial
witch, greater aortic/pulmonary size discrepancy, or the
resence of aortic regurgitation or a residual ventricular
eptal defect at discharge. Nonetheless, even in this
opulation, a secondary slow increase in heart rate occurs
n older patients. Most aortic regurgitation remains
rivial and without consequence, and repeat surgery has
een performed in only 1.4% of survivors.
An editorial by del Nido and Schwartz (119) pointed
ut that the gradual increase in the presence of aortic
egurgitation has been noted in patients after the Ross
rocedure where the pulmonary root is inserted into the
V outflow tract. Progressive aortic regurgitation is
ometimes seen in 90% of these patients, and the long-
erm need for surveillance remains necessary.
Cheung et al. (120) reported a randomized trial of
emote ischemic preconditioning to see whether it would
rovide protection against myocardial ischemic reperfu-
ion injury and systemic inflammation in children under-
oing cardiopulmonary bypass. The remote precondi-
ioning protocol was induced by four 5-min cycles of
ower limb ischemia and a 5-min reperfusion with a blood
ressure cuff 5 to 10 min before bypass. Control subjects
nderwent sham placement (without inflation) of the
lood pressure cuff. Patients included those with ventric-
lar septal defects, AV septal defects, and tetralogy of
allot. The control patients had a higher level of cardiac
roponin I, even after excluding patients with extensive
ight ventricular muscle bundle resections. Inotrope use
n the control group was also increased, and tumor
ecrosis factor alpha levels at 6 h were lower in the study
han in the control group. This is a small clinical study
nvolving ischemic preconditioning using lower-limb
schemia before pulmonary bypass—an interesting con-
ept carried over from CAD valvular surgeries, which
hould be further explored in the congenital heart disease
ilieu.
Senzaki et al. (121) published an important hemody-
amic study related to cardiac function in 17 Fontan
atients (mean age 6.3 years) and 20 patients (mean age T.6 years) with normal biventricular circulation as control
ubjects. Fontan patients were in New York Heart
ssociation functional class I, and none had significant
V valve regurgitation. All had undergone a cavopulmo-
ary connection with a lateral tunnel. Ventricular pres-
ure was measured with a high-fidelity manometer-
ipped catheter, and ventricular cardiac area was
easured by echocardiography. Stroke area and stroke
olume were measured by a catheter-mounted electro-
agnetic probe. Maneuvers examined included increased
eart rate induced by atrial pacing and adrenergic stim-
lation by dobutamine, and steady state beats and expi-
ation were evaluated to look at end-diastolic and end-
ystolic pressure area relationships and dP/dt. Preload
as also varied by inferior vena caval occlusion. The
xpected lower cardiac index and fractional shortening
nd higher central venous pressure were seen in the
ingle-ventricle Fontan groups. Fontan patients had a
aseline increase of afterload and a significantly delayed
elaxation measured by tau. With increased heart rate the
ontan group had decreased systolic pressure and stroke
rea index. In response to dobutamine stimulation, the
ncrease in cardiac index was significantly smaller in the
ontan group, associated with limited preload reserve.
his study provides insight into the extent of abnormal-
ties in young children with good Fontan results and an
symptomatic status. It suggests that efforts to overcome
imitations of the Fontan circulation with medical inter-
entions might be required to improve the long-term
rognosis of these patients. The abnormalities also ex-
lain the known and expected decrease in exercise toler-
nce observed in patients after the Fontan procedure.
reclinical research. NOVEL MECHANISMS AT WORK IN
THEROSCLEROSIS. This year marked continued progress
n our understanding of the underlying mechanisms of
therosclerosis and potential new targets for therapeutic
odulation of this disease. The link between CRP and
he disease process of atherosclerosis has become even
learer. Indeed, Monterol et al. (122) observed that CRP
s a marker of plaque activity and can also participate in
rocesses important in the development of ACS (123).
hey showed that CRP increased levels and activity of
MP-1 and -10 in human umbilical vein endothelial
ells and aortic endothelial cells, which was abolished by
nhibition of p38 and Jun N-terminal kinase pathways.
hey also observed elevated MMP activity in coronary
atients with elevated CRP levels along with co-
ocalization of CRP and MMPs in advanced human
therosclerotic lesions. In other investigations, Marfella
t al. (124) used a very clever design to investigate the
ole of the ubiquitin proteosome pathway in destabilizing
arotid plaques in patients undergoing carotid endarter-
ctomy and given rosiglitazone. The excised plaques
howed enhanced ubiquitin protease activity and inflam-
ation that seemed to be inhibited by rosiglitazone.
hus, a key and “druggable” regulator of inflamma-
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January 30, 2007:509–27 Highlights From JACC in 2006ion—the ubiquitin proteosome pathway—is active in
laque stabilization and can be modulated by a thiazoli-
endione. Finally, Liu et al. (125) took an observation
rom neurology that naloxone inhibits microglial activa-
ion and applied it to the apolipoprotein E (apoE)/
ouse and showed that this drug could reduce macro-
hage activation, inflammation, and neointimal forma-
ion. Thus a well-established compound emerges with a
otentially new application to vascular disease.
EW SIGNALING PATHWAYS IN HEART FAILURE. Car-
iomyopathy is a well-known adverse effect of trastu-
umab (Herceptin) therapy for breast cancer, and other
eceptor tyrosine kinases seem to depress myocardial
unction. Liu at al. (126) showed that the ligand of
rbB2/ErbB4 receptors given to murine and canine
odels of ischemic, dilated, and viral cardiomyopathy
ad salutary effects on cardiac performance, pathological
rocesses, and prolonged survival in each of these models.
his “bedside to bench” study highlights a new pathway
nd possible regulator of heart failure, because the
rbB2/4 signaling has been shown to be a key modulator
f cardiomyocyte apoptosis and survival (127). This
bservation also now provides for the possibility of
esting the hypothesis that neuregulin, the ligand for
rbB2/4, might offer a way to protect the heart in the
etting of cardiotoxic therapeutics in the management of
ancer.
ROGRESS AND ISSUES IN CARDIAC REGENERATION. Al-
hough progress continues in cellular approaches to
ardiovascular disease, there remains controversy and
ncertainty. Anversa et al. (128) and Murry et al. (129)
ave highlighted these in exquisite detail in their view-
oints and commentaries. Anversa et al. (128) argues that
oth bone marrow stem cells and multipotent cardiac
tems show plasticity and ability to differentiate into
ardiomyocytes and vessels, properties that have spirited
heir use in acute MI and heart failure. Murry et al. (129)
rgues that although cellular transplantation has been
hown to improve cardiac function— both from skeletal
yoblasts and bone marrow—the role of cardiac-specific
rogenitors is not clear and that although these cells
ome to the myocardium, it is not clear that they
ransdifferentiate. Moreover, important clinical questions
re discussed: 1) Should stem cell trials be in the clinic
oday? Murry et al. (130) believe that stem cell trials are
arranted on the basis of preclinical safety and efficacy
ata, although 1 report seems to suggest caution. 2) What
s the most appropriate setting for cell therapy: acute
nfarction, heart failure, or both? The answer here is less
lear, and studies in the acute infarct, chronic heart
ailure, and cardiomyopathy are ongoing. 3) What are the
ptimal cells? Right now there is no obvious rationale for
ell choice or mode of delivery. Issues of cell potency,
luripotency, and potential for extracardiac effects (e.g.,
umors) and timing are all important targets for clinicalrials. 4) Which outcome should be used to evaluate this
ew approach? Early on myocardial function is a key
utcome measure, and in the long term we can anticipate
ortality-based trials. In the interim, novel imaging
pproaches (131) and biomarkers will undoubtedly be
eveloped that will aid in the assessment of this very
romising therapeutic modality.
ARDIOVASCULAR GENOMICS. This year brought a new
ection to the Journal in genomics of cardiovascular
edicine. The Journal published State-of-the-Art re-
iews in genomics and personalized medicine (132) and
or whole genome approaches to heart failure (133),
rrhythmias (134), and evaluation of the perioperative
atient (135) as well as the cardiovascular application of
ene expression (136), molecular imaging (137), pro-
eomics (138), endothelial cell progenitors (139), and
ardiac regeneration (128,129). Genomics is now a key
trategy in the diagnosis, prognosis, and management of
atients with cardiovascular disease. With the National
eart, Lung, and Blood Institute’s commitment to ge-
etics and personalized medicine and the more wide-
pread access of genomics technologies to clinical inves-
igators, there will undoubtedly be more to report in 2007
nd beyond in this exciting area of medicine—
ardiovascular genomic medicine.
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